Canarypox virus ALVAC strain containing the FeLV-env, FeLV-gag and FeLV-pol genes from the feline leukemia virus | BCH-LMO-SCBD-45049 | Living Modified Organism | Biosafety Clearing-House

Loading...
  |  

Living Modified Organism (LMO)

Decisions on the LMO Risk Assessments  
published: 01 May 2008 last updated: 06 Sep 2012
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Canarypox virus ALVAC strain containing the FeLV-env, FeLV-gag and FeLV-pol genes from the feline leukemia virus
EN
ALVAC-FL
The recombinant canarypox-feline leukemia virus is known as ALVAC-FL, or vCP97. The attenuated live ALVAC-FL is used as a vaccine against feline leukemia.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
Strain: Canarypox virus ALVAC strain
EN
Characteristics of the modification process
vCP97
EN
  • Other (Homologous recombination )
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-45046-5 Feline leukemia virus envelope glycoprotein | (Feline leukemia virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-45047-4 Feline leukemia virus gag gene | (Feline leukemia virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-45048-4 Feline Leukemia Virus pol gene | (Feline leukemia virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
The genetic sequence of the glycoprotein (FeLV-env gene), a portion of the reverse transcriptase (FeLV-pol gene) and the complete nucleoprotein (FeLV-gag gene) from the feline leukemia virus were inserted into the genomic DNA of a plaque purified isolate of the parent canarypox strain ALVAC.

The transfer of the target genes into ALVAC is done by co-transfecting chicken embryonic fibroblast cells with (i) the expression cassette plasmid into which the target genes (FeLV-env, -gag and -pol) and the promoter had been transferred by the calcium phosphate method and (ii) the rescue canarypox virus (ALVAC strain), causing homologous recombination in the cytoplasm and thus transferring the target gene into ALVAC.

Note: The disease "feline leukemia" is cased by a virus (the "feline leukemia virus", FeLV). FeLV is usually transmitted between infected cats when the transfer of saliva or nasal secretions is involved. If not defeated by the animal’s immune system, the virus can be lethal. Despite the its name, the disease is not a form of cancer. The name stems from the fact that the first disease associated with the virus was a form of leukemia, and by the time it was discovered that the virus was the causal agent, the misleading name was already being used by pet owners.
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
EN
Additional Information
Records referencing this document Show in search
Record type Field Record(s)
Country's Decision or any other Communication Living modified organism(s) 1
Risk Assessment generated by a regulatory process Living modified organism(s) 1